Biontech SE
BNTX98.080USD
0.000
Handelsschluss 09/26, 16:00（ET）Kurse um 15 Minuten verzögert
23.58BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Unternehmen
Unternehmensinformationen
BörsenkürzelBNTX
Name des UnternehmensBiontech SE
IPO-datumOct 10, 2019
CEOProf. Ugur Sahin, M.D.
Anzahl der mitarbeiter6772
WertpapierartDepository Receipt
GeschäftsjahresendeOct 10
AddresseAn der Goldgrube 12
StadtMAINZ
BörseNASDAQ Global Select Consolidated
LandGermany
Postleitzahl55131
Telefon4949613190840
Websitehttps://www.biontech.com/
BörsenkürzelBNTX
IPO-datumOct 10, 2019
CEOProf. Ugur Sahin, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Ramon Zapata Gomez
Mr. Ramon Zapata Gomez
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Ms. Baroness Nicola Blackwood
Ms. Baroness Nicola Blackwood
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Umsatzaufteilung
Währung: USDAktualisiert: Wed, Mar 12
Währung: USDAktualisiert: Wed, Mar 12
FY2019
FY2018
FY2017
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Aktionärsstatistik
Aktualisiert: Sun, Aug 17
Aktualisiert: Sun, Aug 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
AT Impf GmbH
42.37%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.34%
Fidelity Management & Research Company LLC
2.90%
Flossbach von Storch AG
1.76%
Andere
32.93%
Aktionäre
Aktionäre
Anteil
AT Impf GmbH
42.37%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.34%
Fidelity Management & Research Company LLC
2.90%
Flossbach von Storch AG
1.76%
Andere
32.93%
Aktionärstypen
Aktionäre
Anteil
Corporation
60.58%
Investment Advisor
16.91%
Investment Advisor/Hedge Fund
3.59%
Individual Investor
2.11%
Research Firm
1.00%
Hedge Fund
0.83%
Sovereign Wealth Fund
0.63%
Bank and Trust
0.22%
Pension Fund
0.19%
Andere
13.94%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
815
205.26M
85.38%
-4.32M
2025Q1
851
205.71M
85.57%
-4.55M
2024Q4
869
205.33M
85.56%
+3.19M
2024Q3
843
197.46M
82.52%
-2.61M
2024Q2
819
194.42M
81.78%
-7.50M
2024Q1
835
193.57M
81.42%
-10.02M
2023Q4
897
193.24M
81.29%
-7.90M
2023Q3
920
192.71M
79.62%
-7.47M
2023Q2
940
195.49M
80.61%
-8.54M
2023Q1
953
197.88M
81.52%
-6.52M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
AT Impf GmbH
101.85M
42.37%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
16.69%
-304.48K
-0.75%
Mar 31, 2025
Baillie Gifford & Co.
8.16M
3.39%
-60.90K
-0.74%
Mar 31, 2025
Fidelity Management & Research Company LLC
5.95M
2.48%
-495.85K
-7.69%
Mar 31, 2025
Flossbach von Storch AG
4.26M
1.77%
-147.21K
-3.34%
Mar 31, 2025
PRIMECAP Management Company
4.05M
1.68%
-249.39K
-5.81%
Mar 31, 2025
Pfizer Inc
3.66M
1.52%
--
--
Mar 31, 2025
Sahin (Ugur MD)
2.05M
0.85%
-724.50K
-26.11%
Mar 31, 2025
Temasek Holdings Pte. Ltd.
1.81M
0.75%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Sep 6
Aktualisiert: Sat, Sep 6
Name
Anteil
iShares Genomics Immunology and Healthcare ETF
3.71%
Global X Genomics & Biotechnology ETF
3.6%
Langar Global HealthTech ETF
3.46%
First Trust NYSE Arca Biotechnology Index Fund
2.97%
Franklin Genomic Advancements ETF
2.68%
VanEck Biotech ETF
2.65%
WisdomTree BioRevolution Fund
1.8%
Virtus LifeSci Biotech Products ETF
1.74%
iShares Biotechnology ETF
1.44%
ProShares Ultra Nasdaq Biotechnology
1.15%
Mehr Anzeigen
iShares Genomics Immunology and Healthcare ETF
Anteil3.71%
Global X Genomics & Biotechnology ETF
Anteil3.6%
Langar Global HealthTech ETF
Anteil3.46%
First Trust NYSE Arca Biotechnology Index Fund
Anteil2.97%
Franklin Genomic Advancements ETF
Anteil2.68%
VanEck Biotech ETF
Anteil2.65%
WisdomTree BioRevolution Fund
Anteil1.8%
Virtus LifeSci Biotech Products ETF
Anteil1.74%
iShares Biotechnology ETF
Anteil1.44%
ProShares Ultra Nasdaq Biotechnology
Anteil1.15%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
